Inosi Therapeutics develops small molecule inhibitors targeting the Insulin Regulated Aminopeptidase (IRAP) pathway to reverse fibrosis, a condition that leads to tissue scarring and organ dysfunction in chronic diseases. With no existing drugs capable of reversing fibrosis, Inosi's therapies aim to fill a significant gap in treatment options for the 10% of the population affected by fibrotic conditions.
Funding
$4.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IGMUFounders
Product
Problem
Fibrosis, characterized by tissue scarring and organ dysfunction, affects a significant portion of the population and contributes to numerous chronic diseases. Currently, there are limited to no therapeutic options available that can effectively reverse the fibrotic process. This unmet need leaves a substantial gap in treatment for individuals suffering from fibrotic conditions.
Solution
Inosi Therapeutics is developing small molecule inhibitors that target the Insulin Regulated Aminopeptidase (IRAP) pathway, a central mechanism implicated in fibrosis and inflammation. By inhibiting IRAP, Inosi's therapies aim to reverse fibrosis, addressing the underlying cause of tissue scarring and organ damage. This approach offers a potential breakthrough in the treatment of chronic diseases associated with fibrosis, where current options primarily focus on managing symptoms rather than reversing the condition. Inosi's technology is based on collaborative research, and the company is focused on developing first-in-class inhibitors to meet the high unmet need in this therapeutic area.
Target Audience
The primary target audience includes individuals affected by fibrotic conditions, as well as healthcare providers and researchers seeking novel therapies to reverse fibrosis and improve patient outcomes.
Features
- Small molecule inhibitors specifically targeting the IRAP pathway
- Designed to reverse fibrosis and reduce tissue scarring
- Addresses the underlying cause of organ dysfunction in chronic diseases
- Potential application across a range of fibrotic conditions